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Abstract 
Clinical guidelines and health technology assessments are valuable instruments to 
improve the quality of healthcare delivery and aim to integrate the best available 
evidence with real-world, expert context. The role of patient and public involvement 
in their development has grown in recent decades and this article considers the 
international literature exploring aspects of this participation, including the integration 
of experiential and scientific knowledge, recruitment strategies, models of 
involvement, stages of involvement, and methods of evaluation. These 
developments have been underpinned by the parallel rise of public involvement and 
evidence based medicine as important concepts in health policy. Improving the 
recruitment of guideline group chairs, widening evidence reviews to include patient 
preference studies, adapting guidance presentation to highlight patient preference 
points and providing clearer instructions on how patient organisations can submit 
their intelligence are emerging proposals that may further enhance patient and public 
involvement in their processes.   
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Key Points 
 The role of patient and public involvement in the development of clinical 
guidance and standards has grown in recent decades 
 A number of issues have been considered in the international literature 
including the integration of experiential and scientific knowledge, recruitment 
strategies, models of involvement, stages of involvement, and methods of 
evaluation 
 A variety of suggestions have emerged considering ways to advance this 
involvement and make it more meaningful including acknowledging and 
addressing barriers and measuring impact. 
 
Background 
In recent decades, guidelines and health technology assessments have become an 
increasingly important part of healthcare policy and practice around the world [1-3]. 
Rising healthcare costs, expensive technologies, variations in service delivery 
among providers and the intrinsic desire of clinicians to offer the best possible care 
are all factors that have contributed to this rise. Clinical guidelines are systematically 
developed statements that are used to guide healthcare decisions across various 
settings [4, 5]. Health technology assessments are research-based, practice oriented 
assessments of healthcare technologies that support policymakers to introduce new 
technologies to the health system effectively [6]. Quality indicators, meanwhile, are 
measurable items that facilitate improvement in the quality of healthcare practices 
and services [3]. They all share a common approach of robustly evaluating evidence 
and expert knowledge to formulate practical recommendations to achieve 
improvements in healthcare delivery. 
In order to support guideline producing organisations to reach these important goals, 
there has been much international interest in how to improve the quality of guidance 
through standardised methodologies and critical assessment tools [7]. A systematic 
review assessed 24 such assessment instruments from eight different countries, 
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concluding that the Appraisal of Guidelines for Research and Evaluation (AGREE) 
instrument was the highest quality overall [8]. A subsequent systematic review in 
2012 used the AGREE instrument to assess the quality of clinical guidelines 
developed in Europe since 2000, finding that there was considerable room for 
methodological improvements [9]. 
An aspect of guideline quality that has received particular attention is the extent to 
which patients and public are involved in the development process. It has been 
suggested that this involvement has the potential to increase the relevance and 
acceptability of recommendations as patients are likely to have fewer alliances than 
healthcare professionals [10]. However, various barriers to meaningful participation 
have also been cited, including the hierarchical nature of healthcare professions and 
perceived bias in individual viewpoints [11], leading to limited opportunities for input 
and influence. The lack of empirical research about the measurable impact of patient 
and public involvement (PPI) is noteworthy [12] and the diversity of opinion about 
optimal involvement strategies highlights that although PPI is taking place worldwide 
in different forms, it remains an emergent field.  
This review seeks to summarise the current practice of PPI in healthcare guidance 
development and highlight future challenges. Database searches and manual 
reference tracking were used to identify editorials and primary qualitative and 
quantitative research exploring patient involvement in healthcare guidance. 
Decisions about literature inclusion and the shaping of key themes were made 
through consensus meeting of the reviewers. 
 
Stages of involvement 
The production of guidance can be a lengthy process and public involvement can 
take place at multiple stages. Topic selection is the obvious first step, with input at 
this stage considered valuable for both clinical guidelines and health technology 
assessments [13-16]. Similarly, participation in deciding the scope is deemed 
important as it is an opportunity to “set the agenda and determine the rules and the 
players” [17]. Involvement in the formation of recommendations is widely advocated 
[18, 19], along with opportunities to comment on draft versions [15, 18].  
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Patient and public members may also be included in implementation activities [13, 
20, 21, 22], including working with the media and promoting guidance at national and 
regional levels [23]. There is a strong body of support calling for patient and public 
involvement throughout the guideline development process [18, 22, 24, 25].  
 
 
The integration of experiential and scientific knowledge 
The challenge of incorporating patient perspectives alongside scientific evidence 
reflects the conceptual conflicts between evidence based medicine (EBM), which 
relies on objective and robust data, and PPI, which is intrinsically based on the 
experiences of individuals. It has been suggested that this may be resolved by 
providing active support for patient and public members to engage in guidance 
development. For example, the use of scientific and medical terminology by 
guideline developers and health professionals has been identified as a particular 
barrier for patient and public participants [13, 14, 26, 27, 28, 29, 30] and there has 
been reported uncertainty about the extent to which they should be able to interpret 
scientific evidence [14, 27]. Providing critical appraisal training for patient and public 
participants has been widely endorsed [15, 17, 18, 20, 21, 23, 27, 30, 31, 32], 
although it has been found to be resource intensive [23, 27]. However, a contrasting 
perspective is that the unique benefit of PPI comes from experiential learning and 
therefore academic skills are not relevant [28] and indeed, it had been argued that 
they actually weaken participation by reducing the uniqueness of “true” patients “in 
the wild” [33].  
Guideline development is typically performed by a group that includes a chair, 
healthcare professionals from different backgrounds and technical staff from the 
guideline producing organisation [34], along with patient and public members. The 
role of the chair has been widely recognised as being important for effective PPI to 
occur [20, 23, 29, 35, 36]. Although chairs seem to have discordant opinions how 
important active PPI is [36], it has been suggested that they could play an important 
empowering role, with specific proposals including the use of a psychologist chair to 
ensure effective group dynamics [29] and a reminder item on the agenda to consider 
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patient perspectives in each meeting [20]. There was some concern that patient and 
public members may not be actively included in these groups leading to infrequent 
and inappropriate contributions [19, 27], although their presence was felt to be vital 
by others to make discussions less “physician-centric” [24] and keep a focus on the 
right questions.  
There has been considerable interest in understanding how patient preferences can 
be better incorporated into healthcare guidance. Widening search strategies to 
include qualitative research [13, 15, 21, 24, 28, 31, 37], developing new methods to 
synthesise patient preference knowledge [15, 38, 39] and using social scientists to 
review this evidence [21, 37] have all been widely supported. There is, however, an 
impression that this type of evidence is deemed less credible by guideline 
developers and concerns about the extent to which narrative evidence fits into the 
traditional hierarchy of EBM [16, 23, 24, 35, 40]. An additional related mechanism to 
include these perspectives is the addition of relevant key questions for guideline 
development groups to consider.  
In the presentation of guidance, a greater openness about uncertain 
recommendations may help emphasise patient preferences with calls for less firm 
recommendations [41] and more use of menus to present multiple possible 
management strategies [26, 42]. It was also felt that professional versions of 
guidelines could be improved by signalling recommendations that require shared 
decision making and providing links directly to decision aids from the guideline [24, 
38, 31].  
 
Recruitment  
There has often been a lack of clarity about whether lay members should be 
representing themselves or the wider public, with expectations often being unclear 
[14, 15, 16, 33, 36, 38, 43]. Although there have been suggestions that input should 
be exclusively from an individual or general public perspective [25, 33], there seems 
to be recognition that in reality, this is a complex distinction to make [36]. Views 
about the role of patient organisations have been divergent. Whilst there is 
recognition that they can play a variety of roles including submitting evidence and 
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nominating or recruiting members [16, 23], concerns have been raised about the fact 
that some organisations are dependent on industry funding.  
The difficulty recruiting a diverse range of participants has been noted, with 
challenges to recruit representation across age, gender, ethnicity, education and 
socioeconomic dimensions [16, 22, 38, 44]. Stigma is an important consideration 
when recruiting for conditions such as sexual diseases and HIV [45]. Some 
organisations have opted to produce mini ‘job descriptions’ [23, 38] with description 
of the role, task and skills needed. Although these have helped to ensure that 
participants are clear about their roles and have largely been deemed helpful [23], 
the presence of scientific literacy as a desirable trait has been criticised as a barrier 
to achieving genuine representation [42].   
 
Model of involvement 
In her seminal paper on citizen involvement, Sherry Arnstein conceptualised a ladder 
of involvement with 8 steps representing increasingly significant levels of 
involvement in decision-making [46]. Subsequent adaptations of the model have 
focussed particularly on flow of information and have distinguished between 
organisations that use unilateral methods of communication (such as consultation or 
public information) and those that use the preferable bilateral approaches (such as 
active group participation) [17, 31]. Although posting guidance online for public 
comment is a broad and open avenue, it relies on engagement with long documents 
that contain significant amounts of technical information and jargon.  
Public advisory committees such as the Citizen’s Council of the National Institute for 
Health and Care Excellence (NICE) [13, 15, 20, 31, 47] and the Ontarian Health 
Technology Advisory Committee (OHTAC) [44, 48] in Canada are generally highly 
regarded, although the lack of direct input and public will to engage have been noted 
as limitations [13, 47]. The use of priority-setting exercises are a further means to 
seek public advice but their role is limited by the high amount of resources that it 
requires. 
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The composition of guidance producing groups is fundamental, with many 
organisations including one or two lay members routinely [21, 23, 36, 39]. This direct 
involvement and opportunity for discussion has been described as an essential 
feature [24], although contributions can be infrequent and active participation relies 
on a supportive culture [30]. In addition to direct involvement in groups, the use of 
structured peer-facilitation and flipcharts has been found useful [30], although such 
workshops have proven resource intensive [27]. Importantly, the information 
gathered from these workshops is typically fed back to the guideline working group 
by a member of the support team, which means there is no direct interaction 
between the two groups and no means for two-way “knowledge exchange” to occur 
[19, 49]. 
Although patient organisations are generally able to submit evidence to inform 
guidance development [16, 23, 26], there is concern about how it is handled and 
utilised [13, 40]. These organisations may be able to better use their networks and 
knowledge if there was a clearer route for them to contribute their data [50]. Interest 
in using novel ways of engaging the public, such as online platforms and social 
media is also rising [31]. However, there is not yet a clear mechanism by which 
these forms of evidence can be quality assured and synthesised into a form that can 
usefully inform guidance.  
 
Evaluation  
It has widely been suggested that involvement has intrinsic value by promoting 
democracy, redistributing power and allowing patients to influence the health system 
[17, 28, 30, 42, 49]. Thus, PPI may be considered a goal in itself that does not 
require justification and cannot be opposed, other than on methodological grounds 
[42]. Others have argued that it is important in order to gain legitimacy [20, 25, 51], 
increase responsiveness to public need [16] and make guidance easier to implement 
[30, 49].  
Although the lack of formal evaluation of PPI has been criticised [15, 51], there has 
been recognition that randomised-controlled trials (RCTs), for example, would be 
“very difficult if not impossible” to conduct in this area [28]. Indeed, a Cochrane 
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review in 2006 found no published trials evaluating patient involvement in clinical 
guidelines [12] and although none appear to have been published since, a more 
recent cluster RCT across 6 Canadian communities was promisingly able to 
demonstrate that patient involvement can change priorities for healthcare 
improvement at the population level [52]. Of note, there is a lack of published 
evidence about the experiences of patients and public members involved in 
healthcare guidance and this may be an important topic for future research. 
Various instruments have been designed to evaluate guidance quality and although 
the inclusion of a patient involvement dimension in the AGREE checklist has been 
welcomed [28], it may not differentiate meaningful involvement from tokenism and 
has been described as a “blunt instrument” [33] in assessing how patient-centred 
guidance is. The work of international networks has enhanced patient involvement 
[51], although even greater international collaboration would allow organisations to 
further share learning and expertise [38, 53]. Indeed, criticisms of exclusivity and 
tokenism have also been directed to PPI in other areas of healthcare including 
research and improvement activities and models of equitable partnership working 
are being developed [54]. 
 
Conclusions 
The concurrent rise in prominence of EBM and patient involvement in health policy in 
recent decades has been the backdrop to the evolution of PPI in healthcare 
guidance around the world. The inevitable tensions between these two conceptual 
paradigms have given rise to complex challenges faced by guideline developers and 
barriers to designing processes that facilitate meaningful and effective involvement.   
The role of a guideline group chair is particularly important and a greater emphasis 
on ability to facilitate supportive discussions when electing new chairs may help to 
improve this. Although there is no consensus on a single involvement strategy, there 
are circumstances where both individual and broader societal perspectives are 
beneficial. Areas that require unique perspectives such as clinical guidelines may 
benefit more from patients or carers with experiences of a particular condition, 
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whereas members of standing committees for health technology assessment or 
indicators may require public members with societal perspectives.  
Widening search strategies in evidence reviews to include patient preference 
literature has the potential to significantly increase applicability by incorporating a 
broader collection of perspectives. However, this is likely to require a fundamental 
change for guideline developers and necessitate developmental work to establish 
new methods of knowledge synthesis, employment of social scientists to contribute 
to evidence reviews and significant financial investment. Changing the format of 
guidance to highlight the relative uncertainty of recommendations and links to 
decision tools is also an important consideration for the future. 
Healthcare guidance and indicators continue to be a key method to improve health 
systems around the world. Specifically, they improve the quality and experience that 
patients and the public receive from healthcare and ensuring their representation in 
their development is therefore fundamental, whether for reasons of democracy or 
improved quality. This paper provides policymakers and health guidance producers 
with a review of current practices and future challenges relating to PPI. Although 
much progress has been made, further improvements are needed in order to enable 
guideline production that allows meaningful input through both preference 
information and direct involvement.  
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